MALDI-ToF Mass Spectrometry

VeriStrat^®​ Test

• Multivariate test that identifies the chronic elevation of acute phase reactants, which are known to be associated with aggressive cancer
• Impacts treatment strategy and facilitates disease state monitoring

ImmunoStrat^®​ Protein Signatures​

The ImmunoStrat^® suite of protein signatures have been designed to interrogate a patient’s circulating proteome with the goal of predicting response to various immunotherapies across multiple tumor types.

Lung Cancer Risk of Recurrence Test

• We have designed a pre-treatment blood-based protein signature that can identify stage I non-small cell lung cancer patients who have a high-risk of recurrence post-curative resection and may benefit from the addition of adjuvant therapy.
• This test is currently in development.

Biological Pathway Protein Set Scoring

• We have adapted the well-established methods of gene set enrichment analysis (GSEA) to understand protein pathways that are associated with different protein signature test results. ​
• Pathways include: glycolytic processes, complement system, acute response, wound healing, interleukin-10 and immune response type II.

Custom Signature Discovery​

• We design custom protein signatures with our proprietary AI platform to support our partners drug development programs.
• These tests are designed to help answer specific clinical questions, including selecting patients for immunotherapies, novel therapy combinations, or alternative treatment pathways.